AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Investor Day (May 2017)

144 slides from AMAG Pharmaceuticals's investor day presentation, May 24, 2017

  1. Slide 1: Welcome to AMAG's Analyst Day May 24, 2017

    Welcome to AMAG’s Analyst Day May 24, 2017

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AM

  3. Slide 3: Cautionary Disclosure Regarding AMAG's Long-Term Outlook

    3 Cautionary Disclosure Regarding AMAG’s Long-Term Outlook Slides 14, 18, 19, 20 21, 27, 93, 135, 136, 137 and 139 contain forward-looking estimates of AMAG’s growth trajectory in revenue and EBITDA on a multi-year timeframe based on a strategy of increasing revenue diversification by leveraging its

  4. Slide 4: AMAG Executive Team Speakers

    4 AMAG Executive Team Speakers Bill Heiden President and Chief Executive Officer Ted Myles Chief Financial Officer Nik Grund Chief Commercial Officer Julie Krop, MD Chief Medical Officer

  5. Slide 5: Guest Speakers

    5 1 Dr. Simon and Dr. Kagan were compensated for their time and participation in this event and periodically provide consulting services to AMAG. Guest Speakers Risa Kagan, MD, FACOG, CCD, NCMP1 • Clinical Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences, University o

  6. Slide 6: Agenda – AMAG Analyst Day 2017

    6 Agenda – AMAG Analyst Day 2017 Registration and continental breakfast 7:30 am – 8:30 am Welcome and agenda Linda Lennox, VP, Investor Relations Strategic overview and outlook Bill Heiden, President and CEO AMAG products – currently marketed Makena® Feraheme® Cord Blood Registry® (CBR®) Nik Grund,

  7. Slide 7: Strategic Overview & Outlook

    Strategic Overview & Outlook Bill Heiden AMAG President & Chief Executive Officer

  8. Slide 8: Overview

    8 Overview Bremelanotide  Realistic expectations – with upside  Makena  Expect material positive impact on revenues Recent Transactions  Intrarosa  Bremelanotide  Clear growth plans – long runway  Feraheme  CBR  Clear criteria, disciplined approach Business Development

  9. Slide 9: Agenda: AMAG Yesterday and Today; AMAG Tomorrow

    9 Agenda  AMAG: Yesterday and Today  AMAG: Tomorrow

  10. Slide 10: AMAG Yesterday and Today

    10 1 Represents mid point of 2017 financial guidance range. Revenue includes non-GAAP purchase accounting adjustments related to CBR deferred revenue. 2 See slide 143 for a reconciliation of 2017 financial guidance. AMAG Yesterday 2012 2017 E Commercial Products 1 5 Products in Development 0 2 Non-G

  11. Slide 11: Executing Focused 5-Point Strategy

    11 Executing Focused 5-Point Strategy Acquire products with growth potential Strengthened Diverse revenue across multiple commercial products Establish profitability Build drug development capabilities Focus Acquisitions Commercial Platform Diversification Profitability Drug Development Strategy 1 2

  12. Slide 12: What We Have Built: AMAG's Expanded Product Portfolio

    12 What We Have Built: AMAG’s Expanded Product Portfolio Feraheme  Treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease  The only FDA-approved therapy to reduce recurrent preterm birth in certain at-risk women  World’s largest umbilical cord stem cell collection

  13. Slide 13: Solid Execution - Recent Accomplishments

    13 Solid Execution - Recent Accomplishments  Cord Blood Registry  Added more than 40,000 stored units of cord blood and cord tissue  Increased revenue per consumer by 8.5% over 2015  Intrarosa  Rapidly initiated pre-launch activities  Initiated hiring of 150-person women’s health commercial te

  14. Slide 14: Agenda: AMAG Yesterday and Today; AMAG Tomorrow

    14 Agenda  AMAG: Yesterday and Today  AMAG: Tomorrow

  15. Slide 15: Yesterday, Today, Tomorrow

    Yesterday Today Tomorrow3 Commercial Products 1 5 7 Products in Development 0 2 3 Non-GAAP Revenue $85M $660M1 >$1B R&D $33M ~$100M ~$150M Adjusted EBITDA Net loss $235M1,2 ~$350M 15 AMAG 1 Represents mid point of 2017 financial guidance range. Revenue includes non-GAAP purchase accounting adjustmen

  16. Slide 16: An Evolving Strategy

    16 An Evolving Strategy Acquisitions Commercial Platform Diversification Profitability Drug Development Acquire products with growth potential Strengthened Diverse revenue across multiple commercial products Establish profitability Build drug development capabilities Strategy Focus 1 2 3 4 5 Leverag

  17. Slide 17: Makena Franchise 2020 Revenue Expectations

    Makena Franchise 2020 Revenue Expectations

  18. Slide 18: Makena Sub-q & Revenues Depend on the Balance of Factors

    18 Makena Sub-q & Revenues Depend on the Balance of Factors  FDA guidelines regarding comparable bioavailability  Market research data with payers  Strong contracted payer network  Results of Discreet Choice analysis  Timing of availability of IM generics? ‒ Single or multi-dose configuration?

  19. Slide 19: Makena Franchise Revenue Expectations for 2020

    19 Makena Franchise Revenue Expectations for 20201 $0M $500M $1,000M 2017 Low High Middle Makena 2020 1 Represents estimates through 2020. See slide 3 - Cautionary Disclosure Regarding AMAG’s Long-Term Outlook. Makena

  20. Slide 20: Company Revenues Grow in 2020 Under All Makena Scenarios

    High 20 Company Revenues Grow in 2020 Under All Makena Scenarios1 $0M $500M $1,000M 2017 Low Middle 2020 Makena Op. Exp. Flexibility: >90% of operating expenses are variable Feraheme & CBR Intrarosa Bremelanotide Additional Business Development Makena 1 Represents estimates through 2020. See slide 3

  21. Slide 21: Increased Revenue Diversification to Durable Assets

    21 Increased Revenue Diversification to Durable Assets Makena Feraheme CBR Intrarosa Bremelanotide Estimated 2020 Revenue Outlook2 Intrarosa Makena Feraheme CBR >$1B 2017 Non-GAAP Revenue Guidance $630M - $690M1 1 See slide 143 for a reconciliation of 2017 financial guidance. 2 Represents estimates

  22. Slide 22: Key Product Launch Milestones Will Drive Growth

    22 Key Product Launch Milestones Will Drive Growth Bremelanotide Makena subcutaneous auto-injector Revenue Velo (severe preeclampsia) Today 2017 2018 2019 20202 $660M1 IDA (non-CKD) 5 Potential Product Launches over Next 4 Years 1 Represents mid point of 2017 non-GAAP revenue guidance range of $630M

  23. Slide 23: Revenue Potential of >$1 Billion by 2020

    23 Revenue Potential of >$1 Billion by 20201  Realistic expectations – with upside  Makena  Expect material positive impact on revenues Recent Transactions  Intrarosa  Bremelanotide  Clear growth plans – long runway  Feraheme  CBR  Clear criteria, disciplined approach Business Development 

  24. Slide 24: Maternal Health: Makena

    Maternal Health: Makena Nik Grund AMAG Chief Commercial Officer

  25. Slide 25: Makena Agenda

    25 Makena Agenda  Continued Strong Growth in 2017  Maximize the Makena Franchise Opportunity  Sub-q Auto-injector Launch Plan  Market Research Supports Acceptance of Sub-q Auto-injector M A T E R N A L H E A L T H : M A K E N A

  26. Slide 26: Solid Plan to Achieve 2017 Makena Growth

    26 Solid Plan to Achieve 2017 Makena Growth $0 $20 $40 $60 $80 $100 $120 $140 Q4 A Q1 A Q2 A Q3 A Q4 A Q1 A Q2 E Q3 E Q4 E M A T E R N A L H E A L T H : M A K E N A $M  Gain 5 points in market share  Increase average dose per patient  Hold net price stable  2017 ending inventory remains same as

  27. Slide 27: Makena Agenda

    27 Makena Agenda  Continued Strong Growth in 2017  Maximize the Makena Franchise Opportunity  Sub-q Auto-injector Launch Plan  Market Research Supports Acceptance of Sub-q Auto-injector M A T E R N A L H E A L T H : M A K E N A

  28. Slide 28: Makena Franchise Revenue Expectations in 2020

    28 Makena Franchise Revenue Expectations in 2020 $0M $500M $1,000M 2017 High Middle Makena Low 2020

  29. Slide 29: Lifecycle Strategy: Will Maximize Opportunity Beyond 2018

    Lifecycle Strategy: Will Maximize Opportunity Beyond 2018 M A T E R N A L H E A L T H : M A K E N A Initiative Why Important Launch Sub-q Auto-injector 1 Maintain Branded Product 2 Launch Authorized Generic 3 Leverage Breadth 4  Launch Makena sub-q auto-injector, if approved, in Q4-2017 as preferre

  30. Slide 30: Makena Agenda

    Makena Agenda  Continued Strong Growth in 2017  Maximize the Makena Franchise Opportunity  Sub-q Auto-injector Launch Plan  Market Research Supports Acceptance of Sub-q Auto-injector M A T E R N A L H E A L T H : M A K E N A 30

  31. Slide 31: Drive Rapid Conversion to Sub-q Auto-injector

    31 Drive Rapid Conversion to Sub-q Auto-injector1 M A T E R N A L H E A L T H : M A K E N A Key Imperative Effectively communicate the convenience / ease-of-use benefits of sub-q auto-injector Manage the economics relative to generics (price, coding, reimbursement) Improve customer perceptions aroun

  32. Slide 32: Successfully Competing in a Generic Environment

    32 Successfully Competing in a Generic Environment Barrier to Uptake Rationale Medicaid business value proposition M A T E R N A L H E A L T H : M A K E N A Authorized generic to compete for exposed commercial business Generic formulary status helps share in any leakage to generic products Majority

  33. Slide 33: Makena Agenda

    Makena Agenda  Continued Strong Growth in 2017  Maximize the Makena Franchise Opportunity  Sub-q Auto-injector Launch Plan  Market Research Supports Acceptance of Sub-q Auto-injector M A T E R N A L H E A L T H : M A K E N A 33

  34. Slide 34: Sub-q Auto-injector Offers Improved Profile

    Pre-filled, single-use, ergonomic device (one-and-done) Self-contained, small needle – Sub-q needle: 27 gauge, ½” needle – IM needle: 21 gauge, 1½” needle – HPC and patient never see needle – Prevents inadvertent needle pricks Once weekly administration Sub-q in back of arm vs. IM in buttock Dosing

  35. Slide 35: Supportive Research on Makena IM versus Makena Sub-q

    Supportive Research on Makena IM versus Makena Sub-q1,2 Unmet need of administration-related attributes around IM hydroxyprogesterone caproate (HPC) Makena sub-q auto-injector is perceived to perform better than Makena IM and HPC: time for administration, needle length, and needle visibility 1 2 M A

  36. Slide 36: Sub-q Attributes Important to Patients

    36 1 AMAG sponsored “Discrete Choice” patient survey conducted by Trinity Healthcare; n=183. Sub-q Attributes Important to Patients 1% 2% 10% 25% 28% 34% 0% 5% 10% 15% 20% 25% 30% 35% 40% Site of injection Needle thickness Route of administration Needle visibility Needle length Time for administrati

  37. Slide 37: HCPs Expect Convenience Will Drive Compliance and Switching

    37 HCP’s Expect Convenience / Ease-of-Use of Sub-q Will Drive Compliance and Switching1 Expected Impact of Subcutaneous Administration on Compliance and Switching – Post-Profile Exposure M A T E R N A L H E A L T H : M A K E N A Likelihood that patients would be more compliant with sub-q administrat

  38. Slide 38: Makena Sub-q Auto-injector Will be Used in Majority of Treated Patients

    38 Priced Similarly, Makena Sub-q Auto-injector Will be Used in Majority of Treated Patients1 M A T E R N A L H E A L T H : M A K E N A 6% 2% 2% 8% 83% Future Prescribing3 (MDs, n=20) Current Prescribing2 (HCPs, n=30) 8% 18% 67% 0% 0% Makena sub-q4 Makena IM Generic HPC single-dose vial4 Compounded

  39. Slide 39: Payer Perceptions on Sub-q Auto-injector

    39 Payer Perceptions on Sub-q Auto-injector1 M A T E R N A L H E A L T H : M A K E N A 85% (n=9) 2% (n=4) 13% (n=2) Perception of Makena Sub-q Auto-Injector (n=15, weighted by % commercial and Medicaid lives) Drivers for “Favorable” Perception:  Perceived ease-of-use given existing self-injection o

  40. Slide 40: Summary: Comprehensive Plan to Maximize Makena Franchise

     Plan in place to optimize short- and long-term value – Many possible scenarios, AMAG will be ready  Research indicates sub-q auto-injector provides convenience and ease- of-use, driving compliance and switching  Payer acceptance with parity pricing should drive conversion to sub-q  sNDA filed i

  41. Slide 41: Hematology/Oncology: Feraheme

    Hematology/Oncology: Feraheme Julie Krop, MD AMAG Chief Medical Officer Nik Grund AMAG Chief Commercial Officer

  42. Slide 42: Feraheme Agenda

    42 Feraheme Agenda  Label Expansion Background  Phase 3 Study Results and Regulatory Timeline  Competitive Landscape  Market Opportunity with Broad Label  Broad Label Launch Strategy H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E

  43. Slide 43: Background: Feraheme Label Expansion

     Submitted sNDA to expand label to include all IDA patients – Included data from 2 controlled, multi-center Phase 3 trials with more the 1,400 patients – Both studies met the primary efficacy endpoints related to improvements in hemoglobin 43 Background: Feraheme Label Expansion June 2009  Approve

  44. Slide 44: Large Phase 3 Label Expansion Study

    44 Large Phase 3 Label Expansion Study Sample size  ~2,000 patients randomized in a 1:1 ratio Dosing regimen  2 doses of Feraheme (1.02g)* or Injectafer® (1.5g)*, dosed 7 days apart Patient Population  Subjects with IDA and in whom intravenous iron treatment is indicated and have failed previous

  45. Slide 45: Rationale for Injectafer as the Comparator

    45 Rationale for Injectafer as the Comparator  Competitor with a broader label  Similar dosing regimen allows for blinded study  Injectafer requires 50% higher iron dose to achieve similar rise in hemoglobin levels  Injectafer is fastest growing product in IV iron class Rationale     H E M A

  46. Slide 46: Feraheme Agenda

    46 Feraheme Agenda  Label Expansion Background  Phase 3 Study Results and Regulatory Timeline  Competitive Landscape  Market Opportunity with Broad Label  Broad Label Launch Strategy H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E

  47. Slide 47: Achieved Composite Primary Safety Endpoint

    47 1 Non-inferiority margin = 2.6%. 2 All hypersensitivity events (including anaphylaxis) were adjudicated by a blinded independent expert panel of clinicians. Achieved Composite Primary Safety Endpoint H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E 6 (0.60%) 7 (0.70%) Feraheme IV (1.02 g)

  48. Slide 48: Achieved Composite Secondary Safety Endpoint

    48 1 Non-inferiority margin = 3.6%. 2 All hypersensitivity events (including anaphylaxis) were adjudicated by a blinded independent expert panel of clinicians. Achieved Composite Secondary Safety Endpoint H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E Feraheme IV (1.02 g) (n=997) n (%) Inje

  49. Slide 49: Higher Incidence of Hypophosphatemia with Injectafer

    49 1 Blazevic A et al., The Netherlands Journal of Medicine, January 2014, Vol. 72, No. 1. 2 Mani et al., Transplantation: October 15, 2010, Vol. 90, No. 7, pp 804-805. Higher Incidence of Hypophosphatemia with Injectafer H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E Moderate Blood phospho

  50. Slide 50: Achieved Both Secondary Efficacy Endpoints

    50 1 From baseline to week 5. 2 P value for superiority. 3 Pre-specified non-inferiority margin = 0.5g/dL. Achieved Both Secondary Efficacy Endpoints1 H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E • Mean change in hemoglobin/g of iron administered statistically superior to Injectafer • Mea

  51. Slide 51: Estimated Timeline to Market

    2016 2017 2018 51 Estimated Timeline to Market  Targeted FDA approval and launch  First patient in  Enrollment  Filing Feb. H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E

  52. Slide 52: Feraheme Agenda

    52 Feraheme Agenda  Label Expansion Background  Phase 3 Study Results and Regulatory Timeline  Competitive Landscape  Market Opportunity with Broad Label  Broad Label Launch Strategy H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E

  53. Slide 53: Current Competitive IV Iron Landscape

    53 Current Competitive IV Iron Landscape: Only Two Products Currently Have Broad IDA Label Product Attributes Feraheme Ferrlecit® and Nulecit Venofer® INFeD® Injectafer® Manufacturer AMAG Sanofi/Allergan American Regent Allergan American Regent Intellectual Property 2023 Expired Expired Expired 2027

  54. Slide 54: Overall U.S. Non-Dialysis IV Iron Market is Growing

    54 1 Aggregate of Ferrlecit® Brand + generic Sodium Ferric Gluconate. 2 IMS DDD data through week ending 01/02/15. 3 IMS DDD data through week ending 12/30/16. Overall U.S. Non-Dialysis IV Iron Market is Growing 2014 Breakdown of U.S. Non-dialysis IV Iron Market ~918K grams2 2016 Breakdown of U.S. N

  55. Slide 55: Feraheme is a Differentiated Product

    55 Feraheme is a Differentiated Product A full 1-g dose of Feraheme® (ferumoxytol) Injection can be delivered in two IV Infusions Two IV infusion with schedule flexibility of 3 to 8 days apart The recommended Feraheme dose may be readministered to patients with persistent or recurrent IDA Duration o

  56. Slide 56: Feraheme Agenda

    56 Feraheme Agenda  Label Expansion Background  Phase 3 Study Results and Regulatory Timeline  Competitive Landscape  Market Opportunity with Broad Label  Broad Label Launch Strategy H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E

  57. Slide 57: Large IV Iron Market Opportunity of $700M

    57 Large IV Iron Market Opportunity of $700M1,2 Feraheme 26% Other IV irons 74% Current Addressable Market: $350M Additional Addressable Market: $350M ‒ Iron deficiency anemia caused by other diseases – Iron deficiency anemia caused by chronic kidney disease Label expansion doubles our addressable m

  58. Slide 58: IV Iron Market Represents Small Subset of 4.5M IDA Patients

    58 1 Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition. IV Iron Market Represents Small Subset of 4.5M Patients Who Suffer from IDA Opportunity to convert from oral to IV treatments IDA-CKD Patients  Majority under the care of current AMAG call points; hematology / oncology & hospita

  59. Slide 59: Multiple Causes of Iron Deficiency Anemia: Potential Synergies

    59 Multiple Causes of Iron Deficiency Anemia: Potential for Synergies with AMAG’s Sales Forces Anemia Gastrointestinal Inflammation Abnormal Uterine Bleeding Post OP Blood Loss Chronic Kidney Disease1 Malignancies/ Chemotherapy (Internists) (Internists) (Nephrologists) (Hematologists / oncologists)

  60. Slide 60: Feraheme Agenda

    60 Feraheme Agenda  Label Expansion Background  Phase 3 Study Results and Regulatory Timeline  Competitive Landscape  Market Opportunity with Broad Label  Broad Label Launch Strategy H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E

  61. Slide 61: 2017: Maximize Existing Label & Prepare for 2018 Launch

    61 2017: Maximize Existing Label & Prepare for 2018 Launch • Effective targeting of existing and future segments • Leverage AMAG commercial platforms to maximize MCM approach 1. Educate KOLs • Peer to peer interactions & publication plan 2. Leverage Label1 • CKD disease state awareness 3. Enhance Di

  62. Slide 62: Beyond 2017 Focus: Maximizing Feraheme Franchise Opportunity

    62 Beyond 2017 Focus: Maximizing Feraheme Franchise Opportunity to leverage existing resources for future growth H E M A T O L O G Y / O N C O L O G Y : F E R A H E M E Current AMAG Hem/Onc sales and strategic accounts team covers over 90% of total IV iron market Current AMAG Maternal and Women’s He

  63. Slide 63: In Summary: Feraheme Franchise is Strong and Growing

     Clinical trial showed similar safety and efficacy profile of Feraheme as compared to Injectafer  Feraheme is a differentiated IV iron replacement therapy  Broad IDA label, if approved, provides opportunity for both indication expansion and market expansion 63 In Summary: Feraheme Franchise is St

  64. Slide 64: Maternal Health: Cord Blood Registry (CBR)

    Maternal Health: Cord Blood Registry (CBR) Nik Grund AMAG Chief Commercial Officer

  65. Slide 65: Understanding Today's Pregnant Moms

     In 2016, the average age of a first-time mom enrolling with CBR was ~35  ~90% of moms having babies today are millennial moms  Adapting messaging to be relevant to moms having babies in the 20-34 age range 65 Understanding Today’s Pregnant Moms M A T E R N A L H E A L T H : C O R D B L O O D R E

  66. Slide 66: Brand Performance on Key Factors in Cord Blood Banking Decision

    Brand Performance on Key Factors in Cord Blood Banking Decision Alphacord Americord CariCord CorCell CBR CordUse Cryo-cell FamilyCord Lifebank USA Maze StemCyte ViaCord Best history of quality 3% 5% 5% 3% 23% 3% 4% 5% 4% 2% 2% 9% Clear options 3% 6% 7% 4% 16% 2% 3% 5% 6% 2% 5% 11% Safest storage 3%

  67. Slide 67: In Summary

     CBR continues to be the market leader in cord blood and tissue storage  Comprises a business model that provides steady cash flow and high margin recurring revenue 67 In Summary M A T E R N A L H E A L T H : C O R D B L O O D R E G I S T R Y  Market research confirms new messaging is resonating

  68. Slide 68: Q&A Marketed Products

    Q&A Marketed Products: • Makena • Feraheme • CBR

  69. Slide 69: Women's Health: Intrarosa (prasterone)

    Women’s Health: Intrarosa™ (prasterone) Risa Kagan, MD University of California, San Francisco, East Bay Physicians Medical Group Sutter Medical Foundation Fernand Labrie, MD CEO and Founder of Endoceutics Nik Grund AMAG Chief Commercial Officer

  70. Slide 70: Intrarosa Agenda

    70 Intrarosa Agenda  Disease Overview  Mechanism of Action (MOA)  Market Size  Competitive Landscape  Market and Pricing Research  Revenue Potential  Commercial Launch Strategy W O M E N ’ S H E A L T H : I N T R A R O S A

  71. Slide 71: Intrarosa Agenda

    71 Intrarosa Agenda  Disease Overview  Mechanism of Action (MOA)  Market Size  Competitive Landscape  Market and Pricing Research  Revenue Potential  Commercial Launch Strategy W O M E N ’ S H E A L T H : I N T R A R O S A

  72. Slide 72: Prevalence of VVA is Significant in Post-Menopausal Women

    72 Prevalence of VVA is Significant in Post-Menopausal Women W O M E N ’ S H E A L T H : I N T R A R O S A ~50% women suffer from VVA1 64M Post-Menopausal Women in U.S.1 1 Wysocki et al. Management of Vaginal Atrophy: Implications from the REVIVE Survey: Clinical Medicine Insights: Reproductive Heal

  73. Slide 73: Dyspareunia: Sizable Untapped Treatment Market

    Affected, but not currently seeking treatment Utilizing OTC treatments 73 1 Based on IMS SMART Tool NSP and NPA data. 2 AMAG estimates based on: a) Wysocki et al. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clinical Medicine Insights: Reproductive Health 2014:8 23–30; b) King

  74. Slide 74: Intrarosa Agenda

    74 Intrarosa Agenda  Disease Overview  Mechanism of Action (MOA)  Market Size  Competitive Landscape  Market and Pricing Research  Revenue Potential  Commercial Launch Strategy W O M E N ’ S H E A L T H : I N T R A R O S A

  75. Slide 75: Compares Favorably with Existing Intra-vaginal Treatments

    75 Compares Favorably with Existing Intra-vaginal Treatments in Current $1B Estrogen Therapy Market Criteria Current Intra-Vaginal Therapies Intrarosa Administration Vaginal insert or cream by applicator Vaginal insert by applicator Indication Approved for various symptoms of VVA, including dyspareu

  76. Slide 76: Current FDA-Approved VVA/Dyspareunia Products

    76 1 NSP audit from 4/2011/32017 Growth Dynamics Audit. Current FDA-Approved VVA/Dyspareunia Products W O M E N ’ S H E A L T H : I N T R A R O S A Product 2016 Sales1 ($M) Method of Administration Application Active Ingredient Estrace® (Allergan) $423 Vaginal cream Reusable vaginal applicator 100 m

  77. Slide 77: Intrarosa Agenda

    77 Intrarosa Agenda  Disease Overview  Mechanism of Action (MOA)  Market Size  Competitive Landscape  Market and Pricing Research  Revenue Potential  Commercial Launch Strategy W O M E N ’ S H E A L T H : I N T R A R O S A

  78. Slide 78: Opportunities are Significant to Differentiate Intrarosa

    Unique safety profile Non-estrogen treatment2 Differentiated MOA 78 Research1: Opportunities are Significant to Differentiate Intrarosa W O M E N ’ S H E A L T H : I N T R A R O S A    1 Market research sponsored by AMAG and conducted by Roscow Market Research. 2 Locally converted into estrogens

  79. Slide 79: Great Interest in Learning More about Intrarosa

    79 1 Market research sponsored by AMAG and conducted by Roscow Market Research. Research1: Great Interest in Learning More about Intrarosa 2% 5% 40% 51% 58% 43% OB/GYN (n=255) PCP (n=251) Very/Extremely interested Slightly/Somewhat interested Not at all/Not very interested Q27/39. How interested are

  80. Slide 80: Positive Perception of Prasterone After Reviewing Product Description

    80 Research1: Positive Perception of Prasterone After Reviewing Product Description W O M E N ’ S H E A L T H : I N T R A R O S A Perception BEFORE Reviewing Product Description 1% 2% 78% 83% 22% 16% OB/GYN (n=255) PCP (n=251) Very positive Neutral Very negative ▪ Very few physicians familiar with p

  81. Slide 81: Intrarosa Expected to Expand Prescriptions and Take >25% Share

    81 1 Market research sponsored by AMAG and conducted by Roscow Market Research. Research1: Intrarosa Expected to Expand Prescriptions Written for Dyspareunia by 16% and Take >25% Share W O M E N ’ S H E A L T H : I N T R A R O S A Currently (mean %) With Intrarosa & Yuvvexy Available (mean %) Change

  82. Slide 82: Intrarosa Agenda

    82 Intrarosa Agenda  Disease Overview  Mechanism of Action (MOA)  Market Size  Competitive Landscape  Market and Pricing Research  Revenue Potential  Commercial Launch Strategy W O M E N ’ S H E A L T H : I N T R A R O S A

  83. Slide 83: Good Commercial Formulary Status for Existing VVA Products

    83 Good Commercial Formulary Status for Existing VVA Products1 W O M E N ’ S H E A L T H : I N T R A R O S A 76% Unrestricted Commercial Access 94% Unrestricted Commercial Access 98% Unrestricted Commercial Access 89% Unrestricted Commercial Access 93% Unrestricted Commercial Access Preferred Covere

  84. Slide 84: Good Support from Payers on Intrarosa

    84 Good Support from Payers on Intrarosa – Optimism Driven by Differentiated MOA and Possible Safety Benefit [VALUE] (N=9) [VALUE] (N=5) [VALUE] (N=1) [VALUE] (N=5) [VALUE] (N=2) 0% 100% Negative Some Concerns Neutral Optimistic Enthusiastic % o f co ve re d li ve s Managed Medicaid Commercial Incre

  85. Slide 85: Intrarosa Copay Program will be Key for Patient Acceptance

    Acceptable Range ~$13-25 85 Intrarosa Copay Program will be Key for Patient Acceptance W O M E N ’ S H E A L T H : I N T R A R O S A 0% 20% 40% 60% 80% 100% $2 $4 $6 $8 $10 $12 $15 $18 $21 $24 $26 $30 $36 $41 $46 $50 $60 $70 $76 $85 $120 $128 $175 $300 Van Westendorp Pricing Model Total (n=250) Proh

  86. Slide 86: Market Research – Key Takeaways

    86 Market Research1 – Key Takeaways High level of physician interest to prescribe Intrarosa and treat more patients 1 Low degree of payer management and broad access enjoyed by all therapies 2 W O M E N ’ S H E A L T H : I N T R A R O S A 1 Market research sponsored by AMAG and conducted by Roscow M

  87. Slide 87: Dyspareunia: Sizable Untapped Treatment Market

    Affected, but not currently seeking treatment Utilizing OTC treatments 87 1 Based on IMS SMART Tool NSP and NPA data. 2 AMAG estimates based on: a) Wysocki et al. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clinical Medicine Insights: Reproductive Health 2014:8 23–30; b) King

  88. Slide 88: Intrarosa Agenda

    88 Intrarosa Agenda  Disease Overview  Mechanism of Action (MOA)  Market Size  Competitive Landscape  Market and Pricing Research  Revenue Potential  Commercial Launch Strategy W O M E N ’ S H E A L T H : I N T R A R O S A

  89. Slide 89: Well-Planned Phased Approach for Commercial Launch

    Full Campaign NAMS October Phase 3 89 Well-Planned Phased Approach for Commercial Launch W O M E N ’ S H E A L T H : I N T R A R O S A Coming Soon ACOG May 6-9 Phase 1 Commercial Launch Now Available Mid-2017 Phase 2 Patient Engagement Programs Q1-2018 Phase 4 May 2017 Time Sales

  90. Slide 90: Uncover DHEA Debuted at ACOG – Well Received

    90 “Uncover DHEA” Debuted at ACOG – Well Received Greater brand presence at ACOG than past years W O M E N ’ S H E A L T H : I N T R A R O S A Elevate awareness and importance of DHEA

  91. Slide 91: Launch Day – Now Available

    91 Launch Day 1 – Now Available W O M E N ’ S H E A L T H : I N T R A R O S A       Arming the Sales Force Sales training modules / certification Annotated PI leave behind Patient co-pay card brochure Pharmacy intro sheet Co-pay flash card “Now available” ad in journals / online

  92. Slide 92: In Summary

     Differentiated mechanism of action  Only FDA-approved non-estrogen local product1 for dyspareunia due to menopause – Only product without a boxed warning  Strong physician interest to prescribe  Well-planned launch strategy to quickly capture market share  Significant market opportunity with s

  93. Slide 93: Women's Health: Bremelanotide

    Women’s Health: Bremelanotide James Simon, MD Clinical Professor, Dept. of OB/GYN, George Washington University Julie Krop, MD AMAG Chief Medical Officer Nik Grund AMAG Chief Commercial Officer

  94. Slide 94: Bremelanotide Agenda

    94 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H : B

  95. Slide 95: Bremelanotide Agenda

    95 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H : B

  96. Slide 96: Presumed Mechanism of Action (MOA)

    MC4R MC4R Dopamine axon terminal D1 dopamine receptor 96 Presumed Mechanism of Action (MOA) W O M E N ’ S H E A L T H : B R E M E L A N O T I D E HSDD-related dopamine release Treatment of HSDD with bremelanotide Decreased release of dopamine MC4R MC4R Dopamine axon terminal D1 dopamine receptor Bre

  97. Slide 97: Bremelanotide Agenda

    97 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H : B

  98. Slide 98: Phase 3 Programs: Comprehensive, Well Designed Studies

    98 Phase 3 Programs: Comprehensive, Well Designed Studies ▪ Randomized ~1,200 women with HSDD – 1:1 ratio bremelanotide or placebo ▪ Patients self-administered bremelanotide 1.75 mg or placebo using the auto-injector as needed in anticipation of sexual activity – Dose selection based on positive Pha

  99. Slide 99: Phase 3 Outcome Measures: Clearly Defined Endpoints

    99 Phase 3 Outcome Measures: Clearly Defined Endpoints ▪ Co-primary Efficacy Endpoints – Change in Female Sexual Function Index (FSFI): Desire Domain (FSFI-D) Score – Change in Female Sexual Distress Scale: Desire/Arousal/Orgasm (FSDS-DAO) Item 13 Score ▪ Key Secondary Endpoints – Self-assessment of

  100. Slide 100: Key Entry Criteria and Demographics

    Key Demographics1 Age (mean: SD) BMI (kg/m2) (mean: SD) Race: white/AA/other (n: %) Time with HSDD (months) (mean: SD) Bremelanotide 301 Placebo n=319 BMT n=324 38.5 (7.22) 38.4 (6.95) 28.5 (7.3) 28.9 (7.0) 269 (84)/ 42 (13)/ 8 (3) 273 (84)/ 44 (14)/ 7 (2) 49.0 (44) 48.3 (42) Bremelanotide 302 Place

  101. Slide 101: Bremelanotide Agenda

    101 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H :

  102. Slide 102: Met Co-primary Endpoint: Improvement in Desire

    102 P values determined by unadjusted Wilcoxon rank-sum test. Error bars are standard error of the mean. Met Co-primary Endpoint: Improvement in Desire W O M E N ’ S H E A L T H : B R E M E L A N O T I D E Change in FSFI Desire Domain Score from Baseline to End of Core (Double-Blind) Phase 0.24 0.21

  103. Slide 103: Met Co-primary Endpoint: Reduction in Distress

    -0.42 -0.35 -0.71 -0.74 -1. -0.75 -0.5 -0.25 0. Study 301 Study 302 M e a n C h a n g e i n F S D S -D A O I tem 1 3 Placebo Bremelanotide 1.75 mg 103 Met Co-primary Endpoint: Reduction in Distress W O M E N ’ S H E A L T H : B R E M E L A N O T I D E • Compared with placebo, women using bremelanoti

  104. Slide 104: Significant Improvements Across Multiple Secondary Endpoints

    104 Significant* Improvements Across Multiple Secondary Endpoints W O M E N ’ S H E A L T H : B R E M E L A N O T I D E 0.00 0.75 1.50 2.25 3.00 FSFI Total Score FSFI Satisfaction Domain FSFI Orgasm Domain FSFI Lubrication Domain FSFI Arousal Domain Study 301 BMT 1.75 mg Study 301 Placebo Study 302

  105. Slide 105: SSEs Not Effective Endpoint for HSDD

     Difference in number of SSEs not statistically significant  Expert consensus1 that SSE is a poor endpoint for trials evaluating treatments for HSDD – Sexual activity/frequency not considered in the diagnosis  SSEs were required by FDA to attempt to have an objective “countable” endpoint similar

  106. Slide 106: Responder Analysis – Global Assessment Questionnaire

    106 Responder Analysis – Global Assessment Questionnaire Percent Responders Defined by a Score of ≥5 on Question #3 of the Global Assessment Questionnaire 36.1 35.5 58.3 58.2 0. 10. 20. 30. 40. 50. 60. 70. Study 301 Study 302 P erce n t R e s p o n d ers i n G A Q # 3 Bremelanotide 1.75 mg Placebo W

  107. Slide 107: Bremelanotide Agenda

    107 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H :

  108. Slide 108: Favorable Overall Safety Profile in Phase 3 Controlled Studies

    Event Nausea Flushing Headache Bremelanotide 301 n (%) Placebo n=319 BMT n=324 8 (2.5) 138 (42.6) 2 (0.6) 85 (26.2) 8 (2.5) 32 (9.9) Bremelanotide 302 n (%) Placebo n=301 BMT=303 0 112 (37) 1 (0.3) 42 (14.2) 5 (1.7) 37 (12.2) 108 Favorable Overall Safety Profile in Phase 3 Controlled Studies ▪ Most

  109. Slide 109: Bremelanotide Agenda

    109 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H :

  110. Slide 110: Estimated Timeline to Approval

    2016 2017 2018 2019 110 Estimated Timeline to Approval ▪ Targeted FDA approval ▪ Phase 3 studies completed ▪ Complete drug-drug interaction and safety pharmacology studies ▪ NDA submission W O M E N ’ S H E A L T H : B R E M E L A N O T I D E

  111. Slide 111: Bremelanotide Agenda

    111 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H :

  112. Slide 112: Significant Market Opportunity

    Treated (Rx) Presented to HCP, but not treated Not diagnosed 0.5M4 1.6M1,2,4 3.7M 112 1 Rosen et al, Characteristics of premenopausal and postmenopausal women with acquired, generalized HSDD: the HSDD Registry for women 2 Patient segmentation market research sponsored by Palatin Technologies, Inc. a

  113. Slide 113: Bremelanotide Agenda

    113 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H :

  114. Slide 114: 2017 Readiness Strategy in Preparation for Early 2019 Launch

    114 2017 Readiness Strategy in Preparation for Early 2019 Launch W O M E N ’ S H E A L T H : B R E M E L A N O T I D E  Obtain stakeholder insights (HCPs, consumers, payers)  Develop branded campaign and key messages  Finalize packaging and branding elements  Ensure supply chain readiness  Deve

  115. Slide 115: Develop Marketing Strategy Based on Patient Segmentation Research

    115 Develop Marketing Strategy Based on Patient Segmentation Research1 W O M E N ’ S H E A L T H : B R E M E L A N O T I D E Missing Connection  Miss the intimate connection they had with their spouse/ partner and the way they used to feel about sex/sexual desire. Stressed Avoiders  Too busy to ge

  116. Slide 116: Bremelanotide Agenda

    116 Bremelanotide Agenda  Disease Overview and Need  Mechanism of Action (MOA)  Phase 3 Clinical Overview  Co-primary Endpoints Met  Key Safety Data  Regulatory Path and Timeline  Significant Market Opportunity  Launch Readiness Strategy  Recent ACOG Initiatives W O M E N ’ S H E A L T H :

  117. Slide 117: Fostering HSDD Disease Awareness and Education

    117 Fostering HSDD Disease Awareness and Education HSDD Booth HCP HSDD Diagnostic Screener Kit W O M E N ’ S H E A L T H : B R E M E L A N O T I D E

  118. Slide 118: Fostering HSDD Disease Awareness and Education

    118 Fostering HSDD Disease Awareness and Education HSDD Booth HCP HSDD Diagnostic Screener Kit W O M E N ’ S H E A L T H : B R E M E L A N O T I D E

  119. Slide 119: Significant Interest in HSDD

    119 Significant Interest in HSDD W O M E N ’ S H E A L T H : B R E M E L A N O T I D E Product Theater at ACOG “Sexual Desire: Everything You Always Wanted to Know But Were Afraid to Ask” Everything You Wanted to Know But Were Afraid to Ask ▪ Objective: A focused, interactive forum to gather and dis

  120. Slide 120: In Summary: Significant Opportunity in Area of High Unmet Need

     Met co-primary, pre-specified endpoints on desire and distress – Both key symptoms of HSDD – Responder analysis shows results are clinically meaningful to patients  Consistent efficacy across multiple domains of sexual functioning  Favorable safety profile  On track for NDA submission Q1-2018 

  121. Slide 121: Q&A with External Experts

    121 Q&A with External Experts Risa Kagan, MD, FACOG, CCD, NCMP • Clinical Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco • Practicing gynecologist with the East Bay Physicians Medical Group, Sutter Medical Foundation Fernand

  122. Slide 122: Financial Overview

    Financial Overview Ted Myles Chief Financial Officer

  123. Slide 123: Agenda: AMAG Evolution, Capital Allocation, Business Development

    123 Agenda  AMAG Evolution  Capital Allocation  Business Development

  124. Slide 124: A Transformed, Diversified, and Growing Revenue Profile

    124 1 Non-GAAP CBR revenue includes purchase accounting adjustments related to CBR deferred revenue of $19M and $17M for 2015 and 2016, respectively. A Transformed, Diversified, and Growing Revenue Profile 20161 Total Revenue $549M 20151 Total Revenue $437M 2014 Total Revenue $124M 2013 Total Revenu

  125. Slide 125: New Assets will be Key Driver of Growth Beyond 2017

    125 1 See slide 143 for a reconciliation of 2017 financial guidance. 2 Revenue includes purchase accounting adjustments related to CBR deferred revenue. New Assets will be Key Driver of Growth Beyond 2017 20171 Total Non-GAAP Revenue Guidance $630M-$690M Feraheme Makena CBR Intrarosa To build a fran

  126. Slide 126: Agenda: AMAG Evolution, Capital Allocation, Business Development

    126 Agenda  AMAG Evolution  Capital Allocation  Business Development

  127. Slide 127: Consistent Capital Allocation Principles

    127 Consistent Capital Allocation Principles Focus on Shareholder Returns 3  Strong cash position allows us to pursue our strategy, even in challenging markets  Full commitment to value-creating opportunities that we choose to pursue: organic or external  Key criterion in making investment decisi

  128. Slide 128: Revised Liability Profile: BEFORE – Early Maturing Debt Profile

    128 1 Pro forma as of 12/31/17, debt balance assumes $20M from over-allotment option. 2 Approximates weighted average interest rate. 3 Reflects mid-point of financial guidance range. See slide 143 for a reconciliation of 2017 financial guidance. Revised Liability Profile to Align with Business Strat

  129. Slide 129: Revised Liability Profile: AFTER – Extended Debt Maturity Profile

    129 Revised Liability Profile to Align with Business Strategy AFTER – Extended Debt Maturity Profile Key Items Totals Before Totals After Cash1: $500M $321M Outstanding debt balance1: $1,028M $861M Interest rate2: 5.9% 5.9% Total annual interest cost: $60M $50.8M Projected adjusted EBITDA3: $235M $2

  130. Slide 130: Investing Today in Women's Health Supports Long-term Growth

    $0 $500 $1,000 2017 2018 2019 2020 130 Investing Today in Women’s Health Supports Long-term1 Growth 2018 represents near-term period of investment while company continues to generate positive EBITDA Revenue EBITDA ($M) 1 Represents estimates through 2020. See slide 3 - Cautionary Disclosure Regardin

  131. Slide 131: Several Events on the Path to Growth

    131 Several “Events” on the Path to Growth 20171 Total Non-GAAP Revenue $630M-$690M Feraheme Makena CBR Intrarosa Estimated 20202 Revenue Outlook $1B+ Feraheme Makena CBR Intrarosa Bremelanotide Multiple events on the path to growth. AMAG a much stronger company with a sustainable portfolio, plus BD

  132. Slide 132: Agenda: AMAG Evolution, Capital Allocation, Business Development

    132 Agenda  AMAG Evolution  Capital Allocation  Business Development

  133. Slide 133: Business Development is an Important Component of Long-Term Growth Strategy

    133 $0M $500M $1,000M 2017 2020 Makena Feraheme & CBR Intrarosa Bremelanotide Additional Business Development Business Development is an Important Component of Our Long-Term Growth Strategy1 1 Represents estimates through 2020. See slide 3 - Cautionary Disclosure Regarding AMAG’s Long-Term Outlook.

  134. Slide 134: Building Our Portfolio: Consistent Search and Evaluation Criteria

    134 Building Our Portfolio: Consistent Search and Evaluation Criteria  Core therapeutic areas (TAs) (maternal health, hem/onc & select hospital)  Adjacent TAs (women’s health, nephrology) Therapeutic Criteria  Differentiated & durable  Stage of development  Cash payback period and IRR Financial

  135. Slide 135: AMAG's Product Portfolio Extends Across the Continuum of Care in Women's Health

    135 AMAG’s Product Portfolio Extends Across the Continuum of Care in Women’s Health AMAG in 2016 Decision to Get Pregnant • Contraception • Prenatal Vitamins • Infertility Maternal Health • Preterm Birth • Placenta Disorders • Labor Induction • Preeclampsia •Maternal Vitamins Bremelanotide Intrarosa

  136. Slide 136: Financial Profile Strengthened to Support Evolving Business Model

     Balance sheet maturities now align with portfolio  Strong cash balance supportive of additional business development  Positive EBITDA and strong cash flow generation from current products enables investment in future products 136 Financial Profile Strengthened to Support Evolving Business Model

  137. Slide 137: Q&A

    Q&A

  138. Slide 138: Closing Remarks

    Closing Remarks Bill Heiden AMAG President & Chief Executive Officer

  139. Slide 139: AMAG Portfolio: Multiple Value Drivers

    139 AMAG Portfolio: Multiple Value Drivers Milestone 2017 2018 MAKENA AUTO-INJECTOR PROGRAM Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Topline PK data sNDA submission Expected FDA action and commercial launch FERAHEME IDA LABEL EXPANSION Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Enrollment completed Topline data sNDA submission Expecte

  140. Slide 140: Revenue Potential of >$1 Billion by 2020

    140 Revenue Potential of >$1 Billion by 2020  Revenue >$900 M  More durable assets with growth potential  Leverage drug development capabilities  Revenue >$1 billion  More durable assets with growth potential  Leverage commercialization and drug development capabilities Goals 3 years out Breme

  141. Slide 141: AMAG Analyst Day Thank you for coming!

    AMAG Analyst Day Thank you for coming! May 24, 2017

  142. Slide 142: Appendix

    Appendix

  143. Slide 143: Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance

    143 Reconciliation of GAAP to Non-GAAP 2017 Financial Guidance 2017 Financial Guidance ($M) Updated GAAP net income ($88) – ($44) Adjustments: Interest expense, net 71 Provision for income tax expense (benefit) (55) – (26) Operating income (loss) ($72) – $1 Purchase accounting adjustments related to

  144. Slide 144: AMAG Analyst Day Thank you for coming!

    AMAG Analyst Day Thank you for coming! May 24, 2017

AMAG Pharmaceuticals — Investor Day (May 2017) on 6ix